Extrawell Pharmaceutical Holdings Ltd banner
E

Extrawell Pharmaceutical Holdings Ltd
HKEX:858

Watchlist Manager
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Watchlist
Price: 0.083 HKD Market Closed
Market Cap: HK$211.7m

Multiples-Based Value

The Multiples-Based Value of one Extrawell Pharmaceutical Holdings Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 0.083 HKD, Extrawell Pharmaceutical Holdings Ltd is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Extrawell Pharmaceutical Holdings Ltd Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Extrawell Pharmaceutical Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
211.7m HKD 4 -0.6 -22.4 -22.4
US
Eli Lilly and Co
NYSE:LLY
900.7B USD 13.8 43.6 29.4 31.4
US
Johnson & Johnson
NYSE:JNJ
581B USD 6.2 21.7 15.1 18.5
UK
AstraZeneca PLC
LSE:AZN
236B GBP 5.3 30.6 16.9 23.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.2 11.4 12.8
US
Merck & Co Inc
NYSE:MRK
304.8B USD 4.7 16.7 10.3 12.6
CH
Novartis AG
SIX:NOVN
229.9B CHF 5.2 20.8 12.9 16.6
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.5 10.5 7.8 9.1
US
Pfizer Inc
NYSE:PFE
156.2B USD 2.5 20.1 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
119.2B USD 2.5 16.9 7.1 8.8
P/E Multiple
Earnings Growth PEG
HK
E
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Average P/E: 22.2
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.6
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.7
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
30.6
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.2
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.7
14%
1.2
CH
Novartis AG
SIX:NOVN
20.8
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
US
Pfizer Inc
NYSE:PFE
20.1
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
E
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Average EV/EBITDA: 50.5
Negative Multiple: -22.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.4
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.5
UK
AstraZeneca PLC
LSE:AZN
16.9
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.3
3%
3.4
CH
Novartis AG
SIX:NOVN
12.9
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.8
1%
7.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
E
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Average EV/EBIT: 111.4
Negative Multiple: -22.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.5
6%
3.1
UK
AstraZeneca PLC
LSE:AZN
23.8
21%
1.1
CH
Roche Holding AG
SIX:ROG
12.8
6%
2.1
US
Merck & Co Inc
NYSE:MRK
12.6
6%
2.1
CH
Novartis AG
SIX:NOVN
16.6
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett